Menopause-Related Changes in Energy Expenditure: Mechanisms, Clinical Implications, and Management

Abstract

Menopause is a pivotal physiological transition characterized by fluctuations and eventual cessation of ovarian hormone production, leading to a spectrum of metabolic changes. Among these, alterations in energy expenditure play a significant role in modifying body composition and metabolic health. This review synthesizes current scientific evidence on menopause-associated changes in energy expenditure, explores underlying pathophysiological mechanisms, and discusses clinical implications and management strategies for healthcare professionals. Emerging therapies and guideline-based recommendations are highlighted to inform best practices in patient care.

Introduction

The menopausal transition, typically occurring between the ages of 45 and 55, is associated with a host of metabolic adaptations. One of the most clinically relevant yet underappreciated consequences is a reduction in total energy expenditure (TEE), which may predispose women to weight gain, increased adiposity, and heightened cardiometabolic risk. Understanding the trajectory and mechanisms underlying menopause-related energy expenditure changes is essential for developing targeted interventions to optimize health outcomes in midlife women. This article reviews the epidemiology, pathophysiology, clinical features, diagnostic approaches, and evidence-based management of menopause-induced alterations in energy expenditure, with a focus on translating research into clinical practice.

Epidemiology / Disease Burden

Globally, over a billion women are projected to be postmenopausal by 2030, underscoring the public health importance of menopause-related metabolic sequelae. Epidemiological data indicate that nearly two-thirds of postmenopausal women experience notable weight gain and increased central adiposity, both of which are closely linked to decreased energy expenditure. Studies such as the Study of Women’s Health Across the Nation (SWAN) have demonstrated a decline in resting metabolic rate (RMR) of approximately 50–70 kcal/day during the menopausal transition, independent of chronological aging. This modest yet cumulative reduction in energy expenditure substantially increases the risk of obesity, type 2 diabetes, and cardiovascular disease among postmenopausal women, amplifying the clinical burden.

Pathophysiology

Menopause-related changes in energy expenditure are multifactorial. The decline in circulating estradiol exerts profound effects on multiple components of TEE, including RMR, thermic effect of food (TEF), and activity energy expenditure (AEE). Estrogen deficiency impairs mitochondrial function, downregulates brown adipose tissue activity, and alters sympathetic nervous system output, collectively reducing basal and adaptive thermogenesis. Additionally, menopause is associated with a progressive loss of lean muscle mass (sarcopenia), further decreasing RMR. Changes in sleep quality and increased prevalence of depressive symptoms may also reduce spontaneous physical activity and non-exercise activity thermogenesis (NEAT), compounding the energy imbalance.

Risk Factors

Several factors modulate the extent of menopause-related energy expenditure decline. Advancing age, genetic predisposition, pre-existing obesity, sedentary lifestyle, and suboptimal dietary patterns potentiate the reduction in TEE. Early menopause (before age 45), surgical menopause, and coexisting endocrinopathies such as hypothyroidism may exacerbate the metabolic impact. Ethnic variability in body composition and hormonal profiles further influences individual susceptibility to adverse energy balance during the menopausal transition.

Clinical Features

Clinically, the reduction in energy expenditure presents as gradual weight gain, with preferential deposition of adipose tissue in the abdominal region. Patients may report increased difficulty in weight maintenance despite unchanged dietary and activity patterns. Sarcopenic obesity a coexistence of increased fat mass and reduced muscle mass is a distinct phenotype observed in postmenopausal women, contributing to frailty and decreased functional capacity. Additional manifestations may include worsening insulin resistance, dyslipidemia, and elevated blood pressure, all of which are integral components of the metabolic syndrome.

Diagnosis

Assessment of menopause-related changes in energy expenditure requires a comprehensive clinical approach. Indirect calorimetry is the gold standard for measuring RMR but is not routinely available in most clinical settings. Alternatively, predictive equations (e.g., Mifflin-St Jeor) and body composition analysis using dual-energy X-ray absorptiometry (DXA) provide valuable estimates. Clinical evaluation should include anthropometric measurements, assessment of physical activity levels, and a detailed dietary history. Laboratory assessment of hormonal status, glucose metabolism, and lipid profile assists in identifying associated metabolic derangements.

Treatment & Management

Effective management of menopause-associated energy expenditure changes encompasses lifestyle modification as the cornerstone. Structured exercise programs, particularly those incorporating resistance and aerobic training, are crucial for preserving muscle mass and enhancing RMR. Dietary interventions should focus on caloric moderation, increased protein intake to support muscle synthesis, and balanced macronutrient distribution. Behavioral counseling and motivational support facilitate adherence to lifestyle interventions. Pharmacological therapies, including menopausal hormone therapy (MHT), may be considered in select women after individualized risk assessment, as estrogen replacement has been shown to partially mitigate declines in energy expenditure and prevent central adiposity. Comorbidities such as hypothyroidism and mood disorders should be optimally managed.

Recent Advances / Emerging Therapies

Recent research has explored the potential of selective estrogen receptor modulators (SERMs), phytoestrogens, and novel agents targeting brown adipose tissue activation to augment energy expenditure in postmenopausal women. Trials investigating myostatin inhibitors and mitochondrial enhancers are ongoing, aiming to address sarcopenic changes and improve metabolic flexibility. Digital health interventions, including wearable activity trackers and app-based dietary monitoring, are increasingly utilized to promote sustained lifestyle modifications. The role of personalized nutrition and exercise prescriptions based on genetic and metabolic profiling is an emerging frontier in the management of menopause-related metabolic changes.

Guideline Recommendations

International guidelines emphasize the importance of lifestyle interventions as first-line therapy for metabolic changes during menopause. The North American Menopause Society (NAMS) and Endocrine Society guidelines recommend individualized MHT when indicated, with periodic reevaluation of risks and benefits. Consensus statements advocate for regular screening of body composition, metabolic risk factors, and functional status in midlife women. Multidisciplinary care involving gynecology, endocrinology, nutrition, and behavioral health is essential for optimizing outcomes.

Conclusion

Menopause-related changes in energy expenditure represent a clinically significant contributor to adverse metabolic outcomes in midlife women. A nuanced understanding of underlying mechanisms, risk factors, and evidence-based management strategies is vital for healthcare professionals. Early identification and intervention, guided by current clinical guidelines and emerging therapeutic options, can mitigate the burden of weight gain and associated comorbidities, ultimately improving quality of life and long-term health in postmenopausal women.